Literature DB >> 7370800

Role of forebrain catecholamines in amygdaloid kindling.

M E Corcoran, S T Mason.   

Abstract

The rate and pattern of seizure development provoked by repeated electrical stimulation of the amygdala (kindling) was assessed in rats that had been pretreated with intracerebral injections of the selective catecholaminergic neurotoxin 6-hydroxy-dopamine. Rats with selective depletion of forebrain noradrenaline displayed a highly significant facilitation of both primary-site and secondary-site kindling, whereas no such effect occurred in rats with selective depletion of forebrain dopamine. The facilitative effects of noradrenaline depletion were apparently related to disinhibition of the spread of seizure discharge from the stimulated site rather than to increased epileptogenicity in the stimulated site itself. These results are consistent with previous evidence that noradrenaline reduces the susceptibility of the central nervous system to epileptiform activity, and they suggest that a lessening of seizure-suppressant noradrenergic function in the forebrain might be part of the mechanism underlying kindling.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7370800     DOI: 10.1016/0006-8993(80)90289-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  The α2B-adrenergic receptor is mutant in cortical myoclonus and epilepsy.

Authors:  Maurizio De Fusco; Riccardo Vago; Pasquale Striano; Carlo Di Bonaventura; Federico Zara; Davide Mei; Min Seuk Kim; Shmuel Muallem; Yunjia Chen; Qin Wang; Renzo Guerrini; Giorgio Casari
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

2.  A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine.

Authors:  S Janumpalli; L S Butler; L B MacMillan; L E Limbird; J O McNamara
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

3.  Mechanisms of epileptic brain damage: evidence for a protective role of the noradrenergic locus coeruleus system in the rat.

Authors:  G Nevander; M Ingvar; O Lindvall
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

4.  Differential expression of alpha1, alpha2, alpha3, and alpha5 GABAA receptor subunits in seizure-prone and seizure-resistant rat models of temporal lobe epilepsy.

Authors:  M O Poulter; L A Brown; S Tynan; G Willick; R William; D C McIntyre
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

5.  Developmental change of dopamine beta-hydroxylase activity in cerebrospinal fluid of epileptic and non-epileptic children.

Authors:  H Suzuki; M Shimohira; Y Iwakawa; T Nagatsu
Journal:  J Neural Transm Gen Sect       Date:  1990

6.  Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices.

Authors:  M Kokaia; P Aebischer; E Elmér; J Bengzon; P Kalén; Z Kokaia; O Lindvall
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

7.  Pharmacological and neurochemical aspects of kindling.

Authors:  M Schmutz; M Klein; K Klebs; R Bernasconi; H Bittiger; V Baltzer
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  The role of different types of adrenergic receptors in pentylenetetrazol-induced seizures and the effect of di-n-propylacetate in the rat.

Authors:  M Lazarova; C Bendotti; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Seizure suppression in kindling epilepsy by intrahippocampal locus coeruleus grafts: evidence for an alpha-2-adrenoreceptor mediated mechanism.

Authors:  J Bengzon; M Kokaia; P Brundin; O Lindvall
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

10.  Grafted noradrenergic neurons suppress seizure development in kindling-induced epilepsy.

Authors:  D I Barry; I Kikvadze; P Brundin; T G Bolwig; A Björklund; O Lindvall
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.